BioSpace News Archive

Business

Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported its second quarter operating and financial results and reviewed recent business highlights.

August 10, 2023
·
7 min read
Business

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Virios Therapeutics, Inc. today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

August 10, 2023
·
7 min read
Business

HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the second quarter of 2023.

August 10, 2023
·
11 min read
Pharm Country

WindRose Portfolio Company Healthmap Raises $100 Million to Continue Fighting Kidney Disease

WindRose Health Investors, LLC (“WindRose”), a leading healthcare-focused private equity firm, announced that its portfolio company, Healthmap Solutions, Inc. (“Healthmap”), has raised $100 million to support the ongoing expansion of its business.

August 10, 2023
·
4 min read
Business

Exscientia Business Update for Second Quarter and First Half of 2023

Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2023, are summarised below. Exscientia will host a conference call Thursday, August 10 at 1:30 p.m. BST / 8:30 a.m. EDT.

August 10, 2023
·
11 min read
Business

Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update

Addex Therapeutics reported its half-year and second quarter financial results for the periods ended June 30, 2023 and provided a corporate update.

August 10, 2023
·
8 min read
XNK Therapeutics enters into agreement with US-based biotechnology company

XNK Therapeutics AB announced that the company has entered into an agreement with a US biotechnology company.

August 10, 2023
·
2 min read
Drug Development

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

Sosei Group Corporation and Cancer Research UK announce that the first patient has been dosed in a Phase I/IIa clinical trial evaluating Sosei Heptares’ orally available small molecule cancer immunotherapy drug HTL0039732 for advanced solid tumors.

August 10, 2023
·
8 min read
Business

X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program

X4 Pharmaceuticals reported financial results for the second quarter ended June 30, 2023, highlighted key recent and upcoming expected milestones, and presented emerging data from its ongoing Phase 2 clinical trial of mavorixafor in people with certain chronic neutropenic disorders.

August 10, 2023
·
14 min read
Business

IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the second quarter ended June 30, 2023.

August 10, 2023
·
28 min read